Evidence map›Paper›PMID 37420261›Full record

ArticlePilot and feasibility studies2023

Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study.

Rebecca L Gould, Charlotte Rawlinson, Ben Thompson, Kirsty Weeks, Rebecca Gossage-Worrall, Hannah Cantrill, Marc A Serfaty, Christopher D Graham, Lance M McCracken, David White and 25 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 17 institutions in 3 countries.

Rebecca L GouldDivision of Psychiatry, University College London, Wing B, 6th Floor Maple House, 149 Tottenham Court Rd, London, W1T 7NF, UK. r.gould@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9283-1626
Charlotte RawlinsonDivision of Psychiatry, University College London, Wing B, 6th Floor Maple House, 149 Tottenham Court Rd, London, W1T 7NF, UK.
Ben ThompsonClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Kirsty WeeksDivision of Psychiatry, University College London, Wing B, 6th Floor Maple House, 149 Tottenham Court Rd, London, W1T 7NF, UK.
Rebecca Gossage-WorrallClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Hannah CantrillClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Marc A SerfatyDivision of Psychiatry, University College London, Wing B, 6th Floor Maple House, 149 Tottenham Court Rd, London, W1T 7NF, UK.
Christopher D GrahamStrathclyde Psychology, Department of Psychological Sciences & Health, University of Strathclyde, Glasgow, UK.
Lance M McCrackenDepartment of Psychology, Uppsala University, Uppsala, Sweden.
David WhiteClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Robert J HowardDivision of Psychiatry, University College London, Wing B, 6th Floor Maple House, 149 Tottenham Court Rd, London, W1T 7NF, UK.
Matt BursnallClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Mike BradburnClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Ammar Al-ChalabiMaurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
Richard OrrellDepartment of Clinical and Movement Neurosciences, Institute of Neurology, University College London, London, UK.
Suresh K ChhetriLancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK.
Rupert NoadDepartment of Neuropsychology, Derriford Hospital, Plymouth, UK.
Aleksandar RadunovicBarts Health NHS Trust, London, UK.
Tim WilliamsThe Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Carolyn A YoungThe Walton Centre NHS Foundation Trust, Liverpool, UK.
David DickNorfolk and Norwich University Hospital, Norwich, UK.
Vanessa LawrenceHealth Services & Population Research Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Laura H GoldsteinDepartment of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Tracey YoungSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
John EalingManchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK.
Hamish McLeodMental Health and Wellbeing, University of Glasgow, Glasgow, UK.
Nicola WilliamsPrimary Care Clinical Trials Unit, Oxford University, Oxford, UK.
Helen WeatherlyCentre for Health Economics, University of York, York, UK.
Richard CaveLanguage and Cognition, University College London, London, UK.
Theresa ChiweraMaurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
Francesco PagniniDepartment of Psychology, Università Cattolica del Sacro Cuore, Milan, Italy.
Cindy CooperClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Pamela J ShawSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Christopher J McDermottSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
and the COMMEND Collaboration Group
University of Sheffield · GBUniversity College London · GBKing's College London · GBBarts Health NHS Trust · GBDerriford Hospital · GBLancashire Teaching Hospitals NHS Foundation Trust · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBNorfolk and Norwich University Hospital · GBSalford Royal NHS Foundation Trust · GBThe Priory Hospital · GBUniversità Cattolica del Sacro Cuore · ITUniversity of Glasgow · GBUniversity of Liverpool · GBUniversity of Oxford · GBUniversity of Strathclyde · GBUniversity of York · GBUppsala University · SE

Funding

Medical Research Council MR/R024804/1Motor Neurone Disease Association Gould/Jul17/936-794
6 · The paper itself

Abstract

backgroundMotor neuron disease (MND) is a fatal, progressive neurodegenerative disease that causes progressive weakening and wasting of limb, bulbar, thoracic and abdominal muscles. Clear evidence-based guidance on how psychological distress should be managed in people living with MND (plwMND) is lacking. Acceptance and Commitment Therapy (ACT) is a form of psychological therapy that may be particularly suitable for this population. However, to the authors' knowledge, no study to date has evaluated ACT for plwMND. Consequently, the primary aim of this uncontrolled feasibility study was to examine the feasibility and acceptability of ACT for improving the psychological health of plwMND.

methodsPlwMND aged ≥ 18 years were recruited from 10 UK MND Care Centres/Clinics. Participants received up to 8 one-to-one ACT sessions, developed specifically for plwMND, plus usual care. Co-primary feasibility and acceptability outcomes were uptake (≥ 80% of the target sample [N = 28] recruited) and initial engagement with the intervention (≥ 70% completing ≥ 2 sessions). Secondary outcomes included measures of quality of life, anxiety, depression, disease-related functioning, health status and psychological flexibility in plwMND and quality of life and burden in caregivers. Outcomes were assessed at baseline and 6 months.

resultsBoth a priori indicators of success were met: 29 plwMND (104%) were recruited and 76% (22/29) attended ≥ 2 sessions. Attrition at 6-months was higher than anticipated (8/29, 28%), but only two dropouts were due to lack of acceptability of the intervention. Acceptability was further supported by good satisfaction with therapy and session attendance. Data were possibly suggestive of small improvements in anxiety and psychological quality of life from baseline to 6 months in plwMND, despite a small but expected deterioration in disease-related functioning and health status.

conclusionsThere was good evidence of acceptability and feasibility. Limitations included the lack of a control group and small sample size, which complicate interpretation of findings. A fully powered RCT to evaluate the clinical and cost-effectiveness of ACT for plwMND is underway.

trial registrationThe study was pre-registered with the ISRCTN Registry (ISRCTN12655391).

Indexed as

AcceptabilityAcceptance and Commitment TherapyFeasibilityMotor neuron diseasePsychological health

Identifiers

PMID37420261
PMCPMC10327371
OpenAlexW4383534888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.